<DOC>
	<DOCNO>NCT02987556</DOCNO>
	<brief_summary>The study conduct crossover trial , two 12-weeks period separate Wash-out period least one month . According randomization , patient provide either Diabeloop system usual system . Patients trained use blood glucose meter , external Insulin Pump Diabeloop system . In treatment period , blood glucose meter use throughout duration study . In two center ( Centre Hospitalier Sud-Francilien Grenoble ) , pre-study perform four week improve efficacy Diabeloop system data collection , test manual setting health care provider patient check good-working follow-up platform .</brief_summary>
	<brief_title>Diabeloop WP7 : Crossover Evaluation Safety Efficacy Artificial Pancreas Diabeloop ( WP7 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Type 1 diabetic patient least two year Patient treat external insulin pump least 6 month Patient HbA1c ≤ 10 % ; dosage le 4 month do analysis laboratory medical equivalent . Patient require daily dose insulin ≤ 50 unit Patient domicile area Global System Mobile Communication ( GSM ) Not isolated patient , live alone , person `` resource '' live nearby phone key place residence Patient envisage journey outside France `` closedloop '' period Patient age 18 year Patient affiliate Social Security Patient agree participate study sign informed consent Patient serious illness may impair study participation Patient treatment know significant interference glycemia . Patient enjoy measure legal protection Pregnant woman likely</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>